Date: 2017-09-19
Type of information: Private placement
Company: Epizyme (USA - MA)
Investors:
Amount: $151.3 million
Funding type: private placement
Planned used: Epizyme anticipates using the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities to fund global development costs of tazemetostat outside of Japan , including the costs of its ongoing and planned clinical trials of and regulatory activities related to tazemetostat; to initiate supply chain and market development activities and prepare for the commercial launch of tazemetostat, if approved; to fund research and development costs to identify and develop other product candidates; and for working capital and other general corporate purposes. Based on its current operating plan, Epizyme expects that the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, will enable it to fund its operating expenses and capital expenditure requirements at least into the third quarter of 2019
Others:
- • On September 19, 2017, Epizyme announced the closing of its public offering of 10,557,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. The shares of common stock issued and sold in the offering at the closing include 1,377,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price less the underwriting discount.
- The aggregate net proceeds before expenses to Epizyme from the offering are approximately $151.3 million , after deducting underwriting discounts and commissions.
- • On September 14, 2017, Epizyme announced the pricing of an underwritten public offering of 9,180,000 shares of its common stock at a price of $15.25 per share, before underwriting discounts. In addition, Epizyme has granted the underwriters a 30-day option to purchase up to an additional 1,377,000 shares of common stock at the public offering price, less the underwriting discount. All of the shares in the offering are to be sold by Epizyme .
- Epizyme anticipates the total gross proceeds from the offering (before deducting underwriting discounts and offering expenses) will be approximately $140 million , excluding any exercise of the underwriters' option to purchase additional shares.
- The offering is expected to close on or about September 18, 2017 , subject to customary closing conditions.
- • On September 13, 2017, Epizyme announced that it intends to offer and sell $120 million of shares of its common stock in an underwritten public offering. Epizyme also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Epizyme .
- Morgan Stanley, Jefferies and Leerink Partners are acting as joint book-running managers for the proposed offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area: Cancer - Oncology
Is general: Yes
